- $2.46m
- $0.79m
- $0.13m
NASDAQ RESUMED AT 09:39 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
U.S. STOCKS ON THE MOVE-Merck, Alibaba, BlackRock
VivoSim Labs soars on robust forecast, Lilly milestone payment
Brief: Vivosim Announces Pricing Of Up To A $4 Million Public Offering
Brief: Vivosim Appoints Arumugham (Ragoo) Raghunathan As Vice President Of Global Sales
Brief: Vivosim Labs Appoints Amar Sethi, M.D., Ph.D. As Chief Scientific Officer
Brief: VivoSim Presents Best-In-Class Liver Toxicology Prediction Results At Digestive Disease Week Conference
Brief: Organovo Holdings Inc Name Change To VivoSim Labs Effective April 24, 2025
Brief: Organovo Holdings Inc Receives Upfront Payments From FXR Program Sale To Lilly
Brief: Organovo Announces Close Of Sale Of FXR Program To Eli Lilly And Company
Brief: Matinas BioPharma Appoints Seasoned Biotech Leaders To Board Of Directors
U.S. STOCKS ON THE MOVE-Maze Therapeutics, UFP Technologies, Itron
Organovo rises five-fold as Eli Lilly acquires co's FXR program
U.S. STOCKS ON THE MOVE-AxoGen, Portillo, Cisco Systems
Brief: Organovo’S FXR Program, Including FXR314, To Be Acquired By Eli Lilly And Company
U.S. STOCKS ON THE MOVE- Eli Lilly, Krispy Kreme, PayPal
Organovo rises as Eli Lilly acquires co's FXR program
Organovo Holdings Inc reports results for the quarter ended December 31 - Earnings Summary